RT Journal Article
SR Electronic
T1 Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 1267
OP 1274
DO 10.1136/heartjnl-2013-303778
VO 99
IS 17
A1 Roberto Diletti
A1 Hector M Garcia-Garcia
A1 Christos V Bourantas
A1 Robert Jan van Geuns
A1 Nicolas M Van Mieghem
A1 Pascal Vranckx
A1 Yao-Jun Zhang
A1 Vasim Farooq
A1 Javaid Iqbal
A1 Joanna J Wykrzykowska
A1 Ton de Vries
A1 Michael Swart
A1 Yvonne Teunissen
A1 Manuela Negoita
A1 Frank van Leeuwen
A1 Sigmund Silber
A1 Stephan Windecker
A1 Patrick W Serruys
A1 On behalf of RESOLUTE All Comers Investigators
YR 2013
UL http://heart.bmj.com/content/99/17/1267.abstract
AB Objective We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES). Design Post hoc analysis of a randomised, multicentre, non-inferiority trial. Setting Multicentre study. Patients All comers study with minimal exclusion criteria. Interventions Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups. Main outcomes measures Clinical outcomes within 2-year follow-up. Results A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419). Conclusions The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.